S&P 500   3,147.35 (+0.61%)
DOW   27,237.42 (+0.58%)
QQQ   217.91 (+1.18%)
AAPL   293.91 (+2.02%)
FB   198.67 (+0.97%)
MSFT   171.35 (+1.95%)
GOOGL   1,397.28 (+0.79%)
AMZN   1,986.06 (+0.68%)
CGC   20.00 (+1.94%)
NVDA   269.64 (+2.90%)
BABA   210.86 (+2.55%)
GE   11.19 (-1.15%)
TSLA   799.04 (-0.11%)
AMD   48.16 (+1.24%)
T   37.47 (+0.32%)
ACB   1.52 (+0.00%)
F   7.36 (+1.66%)
NFLX   375.07 (+4.16%)
BAC   30.97 (-0.35%)
DIS   125.38 (-2.19%)
S&P 500   3,147.35 (+0.61%)
DOW   27,237.42 (+0.58%)
QQQ   217.91 (+1.18%)
AAPL   293.91 (+2.02%)
FB   198.67 (+0.97%)
MSFT   171.35 (+1.95%)
GOOGL   1,397.28 (+0.79%)
AMZN   1,986.06 (+0.68%)
CGC   20.00 (+1.94%)
NVDA   269.64 (+2.90%)
BABA   210.86 (+2.55%)
GE   11.19 (-1.15%)
TSLA   799.04 (-0.11%)
AMD   48.16 (+1.24%)
T   37.47 (+0.32%)
ACB   1.52 (+0.00%)
F   7.36 (+1.66%)
NFLX   375.07 (+4.16%)
BAC   30.97 (-0.35%)
DIS   125.38 (-2.19%)
S&P 500   3,147.35 (+0.61%)
DOW   27,237.42 (+0.58%)
QQQ   217.91 (+1.18%)
AAPL   293.91 (+2.02%)
FB   198.67 (+0.97%)
MSFT   171.35 (+1.95%)
GOOGL   1,397.28 (+0.79%)
AMZN   1,986.06 (+0.68%)
CGC   20.00 (+1.94%)
NVDA   269.64 (+2.90%)
BABA   210.86 (+2.55%)
GE   11.19 (-1.15%)
TSLA   799.04 (-0.11%)
AMD   48.16 (+1.24%)
T   37.47 (+0.32%)
ACB   1.52 (+0.00%)
F   7.36 (+1.66%)
NFLX   375.07 (+4.16%)
BAC   30.97 (-0.35%)
DIS   125.38 (-2.19%)
S&P 500   3,147.35 (+0.61%)
DOW   27,237.42 (+0.58%)
QQQ   217.91 (+1.18%)
AAPL   293.91 (+2.02%)
FB   198.67 (+0.97%)
MSFT   171.35 (+1.95%)
GOOGL   1,397.28 (+0.79%)
AMZN   1,986.06 (+0.68%)
CGC   20.00 (+1.94%)
NVDA   269.64 (+2.90%)
BABA   210.86 (+2.55%)
GE   11.19 (-1.15%)
TSLA   799.04 (-0.11%)
AMD   48.16 (+1.24%)
T   37.47 (+0.32%)
ACB   1.52 (+0.00%)
F   7.36 (+1.66%)
NFLX   375.07 (+4.16%)
BAC   30.97 (-0.35%)
DIS   125.38 (-2.19%)
Log in

NASDAQ:PAVM - PAVmed Stock Price, Forecast & News

$2.53
-0.40 (-13.65 %)
(As of 02/26/2020 12:43 PM ET)
Today's Range
$2.34
Now: $2.53
$2.92
50-Day Range
$1.15
MA: $1.81
$3.29
52-Week Range
$0.81
Now: $2.53
$3.45
Volume1.99 million shs
Average Volume1.45 million shs
Market Capitalization$96.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PAVM
CUSIPN/A
Phone212-949-4319

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.17) per share

Profitability

Net Income$-17,970,000.00

Miscellaneous

Employees9
Market Cap$96.42 million
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable

Receive PAVM News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.


PAVmed (NASDAQ:PAVM) Frequently Asked Questions

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

How were PAVmed's earnings last quarter?

PAVmed Inc (NASDAQ:PAVM) posted its quarterly earnings data on Thursday, November, 15th. The company reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.04. View PAVmed's Earnings History.

When is PAVmed's next earnings date?

PAVmed is scheduled to release their next quarterly earnings announcement on Thursday, April 2nd 2020. View Earnings Estimates for PAVmed.

What price target have analysts set for PAVM?

1 equities research analysts have issued twelve-month price targets for PAVmed's shares. Their forecasts range from $3.00 to $3.00. On average, they expect PAVmed's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for PAVmed.

What is the consensus analysts' recommendation for PAVmed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed.

Has PAVmed been receiving favorable news coverage?

Media coverage about PAVM stock has trended very positive on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PAVmed earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for PAVmed.

Are investors shorting PAVmed?

PAVmed saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 832,500 shares, a drop of 10.3% from the January 15th total of 928,100 shares. Based on an average trading volume of 576,000 shares, the short-interest ratio is currently 1.4 days. Approximately 3.1% of the shares of the company are sold short. View PAVmed's Current Options Chain.

Who are some of PAVmed's key competitors?

What other stocks do shareholders of PAVmed own?

Who are PAVmed's key executives?

PAVmed's management team includes the folowing people:
  • Dr. Lishan Aklog M.D., Chairman & CEO (Age 53)
  • Mr. Dennis M. McGrath CPA, Pres, CFO & Sec. (Age 62)
  • Dr. Brian J. deGuzman M.D., Chief Medical Officer (Age 54)
  • Mike Havrilla, Director of Investor Relations
  • Mr. Shaun M. O'Neil, Chief Commercial Officer

Who are PAVmed's major shareholders?

PAVmed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Levin Capital Strategies L.P. (0.16%) and Virtu Financial LLC (0.05%). Company insiders that own PAVmed stock include Dennis M Mcgrath, Ira Scott Greenspan and Lishan Aklog. View Institutional Ownership Trends for PAVmed.

Which institutional investors are buying PAVmed stock?

PAVM stock was acquired by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P. and Virtu Financial LLC. Company insiders that have bought PAVmed stock in the last two years include Dennis M Mcgrath and Lishan Aklog. View Insider Buying and Selling for PAVmed.

How do I buy shares of PAVmed?

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $2.45.

How big of a company is PAVmed?

PAVmed has a market capitalization of $93.37 million. PAVmed employs 9 workers across the globe.View Additional Information About PAVmed.

What is PAVmed's official website?

The official website for PAVmed is http://www.pavmed.com/.

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]


MarketBeat Community Rating for PAVmed (NASDAQ PAVM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  178 (Thanks for Voting!)
Underperform Votes:  169 (Thanks for Voting!)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote "Outperform" if you believe PAVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel